Market Closed -
OTC Markets
03:59:50 2024-04-26 pm EDT
5-day change
1st Jan Change
0.1325
USD
+2.32%
+1.92%
-5.36%
Presentation Operator MessageOperator (Operator)Good morning, ladies and gentlemen, and welcom...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024
Feb. 15
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Feb. 14
CI
Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System Stimulant
Dec. 26
CI
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR to Marketing Partner Prasco, LLC
Dec. 12
CI
Transcript : Elite Pharmaceuticals, Inc., Q2 2024 Earnings Call, Nov 15, 2023
Nov. 15
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Nov. 14
CI
Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic Product
23-09-25
CI
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
23-09-07
CI
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
23-08-28
CI
Transcript : Elite Pharmaceuticals, Inc., Q1 2024 Earnings Call, Aug 15, 2023
23-08-15
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
23-08-14
CI
Transcript : Elite Pharmaceuticals, Inc., 2023 Earnings Call, Jun 30, 2023
23-06-30
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
23-06-29
CI
Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial Officer
23-05-03
CI
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
23-04-20
CI
Elite Pharmaceuticals, Inc. Announces Resignation of Robert Chen as Treasurer and Secretary
23-02-28
CI
Elite Pharmaceuticals, Inc. Announces Resignation of Robert Chen as Chief Financial Officer
23-02-28
CI
Transcript : Elite Pharmaceuticals, Inc., Q3 2023 Earnings Call, Feb 15, 2023
23-02-15
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
23-02-14
CI
Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence Study
23-02-07
CI
Transcript : Elite Pharmaceuticals, Inc., Q2 2023 Earnings Call, Nov 15, 2022
22-11-15
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
22-11-14
CI
Elite Pharmaceuticals Inc. and Lannett Company, Inc. Jointly Terminated the License, Supply and Distribution Agreement for Vigabatrin
22-11-10
CI
Elite Pharmaceuticals, Inc. Appoints Kirko Kirkov as Chief Commercial Officer
22-09-07
CI
Elite Pharmaceuticals Inc. Receives Notification from Lannett Company, Inc. for Terminating the License, Supply and Distribution Agreement
22-08-26
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Companyâs segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Companyâs products include Phentermine HCl 37.5mg tablets, Phendimetrazine Tartrate 35mg tablets, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
More about the company
1st Jan change
Capi.
-5.36% 142M +19.62% 43.34B +20.44% 21.96B +10.86% 14.09B +13.07% 13.64B +37.46% 11.43B -8.59% 6.86B -0.05% 6.79B -8.87% 5.73B +8.46% 5.22B
Generic Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1